COMMUNIQUÉS West-GlobeNewswire

Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
16/04/2024
Human Pharma sales up 10.3%* to EUR 20.8 bn, driven by JARDIANCE® and OFEV® Animal Health sales up 6.9 %* to EUR 4.7 bn, fueled by new product launches R&D expenditures increase by 14.2% to EUR 5.8 bn Boehringer [...]
CancerVax Announces Promising New Drug to Treat a Deadly Children’s Cancer
16/04/2024
Company plans to launch FDA IND enabling studies needed to apply for approval to proceed with human trials Santa Barbara, April 16, 2024 (GLOBE NEWSWIRE) -- Santa Barbara, CA, April 16, 2024 (GLOBE NEWSWIRE) -- [...]
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
16/04/2024
NBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing through Phase 2 clinical development under a multi-program collaboration with Neurocrine Biosciences Successful completion of a long-term [...]
Faron Confirms Plans for the Coming Months Under New Leadership
16/04/2024
Initial data from ongoing Phase 2 part of BEXMAB trial anticipated next month Incoming CEO, Juho Jalkanen, to accelerate discussions with US regulator to coordinate plans for obtaining marketing approval for MDS [...]
Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024
16/04/2024
Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024 Halle (Saale) / Munich, Germany, April 16, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; [...]
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
16/04/2024
ADHERE data show VYVGART ® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of [...]
StateHouse Appoints Felicia Snyder as Independent Chair of the Board
16/04/2024
Provides Update on Annual Filings Timing SAN DIEGO and TORONTO, April 15, 2024 (GLOBE NEWSWIRE) -- StateHouse Holdings Inc . (“StateHouse” or the “Company”) (CSE: STHZ) (OTCQB: STHZF), a California-focused, vertically [...]
Foundation for Sarcoidosis Research and Walgreens Unite in Alabama to Boost Sarcoidosis Awareness and Spring Vaccine Education for April Awareness Month
16/04/2024
CHICAGO, April 15, 2024 (GLOBE NEWSWIRE) -- Beginning April 15 th , Walgreens, a pharmacy and retail leader who plays a critical role in the U.S. healthcare system by providing a wide range of pharmacy and healthcare [...]
TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation
16/04/2024
FDA Fast Track designation granted for TLX101-CDx for glioma (brain cancer) imaging Collaboration agreement announced for joint development and commercialisation with UCSF PharmaLogic announced as commercial [...]
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
15/04/2024
Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be reported in the third quarter of 2024 Cash runway [...]
AVITA Medical to Announce First Quarter 2024 Financial Results
15/04/2024
VALENCIA, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin [...]
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
15/04/2024
The oral presentation highlighted data from Zevra’s Expanded Access Program demonstrating a consistent safety profile CELEBRATION, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) ( [...]
BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement
15/04/2024
MISSISSAUGA, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has [...]
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
15/04/2024
ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the [...]
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
15/04/2024
Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations Additionally, the company initiated an extension cohort to [...]
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
15/04/2024
MONTREAL, April 15, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of [...]
Theratechnologies annonce l’envoi de sa circulaire de sollicitation de procurations en vue de l’assemblée annuelle des actionnaires
15/04/2024
MONTRÉAL, 15 avr. 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une entreprise biopharmaceutique axée sur la mise au point et la commercialisation [...]
GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents
15/04/2024
Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients [...]
GENFIT : Assemblée Générale Mixte du 22 mai 2024 — modalités de mise à disposition des documents préparatoires
15/04/2024
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 15 avril 2024 – GENFIT (Nasdaq et Euronext : GNFT) , société biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie [...]

Pages